Also trades as: CHM.AX (ASX) · $vol 0M
CHMMF OTC
Chimeric Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
$0.10
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
-100.0% ▼
Operating Income
-$8M
+44.8% ▲
Net Income
-$19M
-80.1% ▼
EPS (Diluted)
$-0.61
+20.8% ▲
EBITDA
-$8M
+8.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $3M | $5M | $0 | $4M | $0 |
| YoY Growth | +0.0% | +72.2% | -100.0% | +0.0% | -100.0% |
| Cost of Revenue | $950K | $0 | $4K | $847K | $0 |
| Gross Profit | $2M | $5M | -$4K | $3M | $0 |
| Gross Margin | 63.7% | 100.0% | — | 78.7% | — |
| R&D Expenses | $6M | $14M | $11M | $10M | $3M |
| SG&A Expenses | $11M | $12M | $10M | $7M | $5M |
| Operating Expenses | $17M | $29M | $21M | $18M | $8M |
| Operating Income | -$15M | -$25M | -$21M | -$15M | -$8M |
| Operating Margin | -576.7% | -556.6% | — | -380.8% | — |
| Interest Expense | $640K | $774K | $332K | $211K | $0 |
| Income Before Tax | -$16M | -$25M | -$21M | -$10M | -$19M |
| Tax Expense | $164K | $93K | -$9M | $111K | $22K |
| Net Income | -$16M | -$26M | -$13M | -$10M | -$19M |
| Net Margin | -607.5% | -566.0% | — | -262.8% | — |
| EPS (Diluted) | $-0.04 | $-0.06 | $-0.02 | $-0.01 | $-0.61 |
| EBITDA | -$14M | -$24M | -$11M | -$9M | -$8M |
| Shares Outstanding | 360M | 433M | 696M | 1.35B | 31M |